BridgeMD
New treatment option for Ovarian Cancer
Official title A Phase 1 Study of LNCB74 in Advanced Solid Tumors
ClinicalTrials.gov ID: NCT06774963
What this study is testing
What is LNCB74?
LNCB74 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for ovarian cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- The participant provides written informed consent
- ≥ 18 years of age on day of signing informed consent.
- Participant with histologically or cytologically confirmed diagnosis of advanced unresectable and/or metastatic solid tumors
- A male participant must agree to use contraception and refrain from sperm donation or expecting to father a child
- A female participant is eligible to participate if she is not pregnant, not breastfeeding, not a woman of childbearing potential
You likely can't join if
- A WOCBP who has a positive serum pregnancy test (within 72 hours) prior to treatment.
- Has received prior investigational agents within 4 weeks prior to treatment.
- Has received anti-cancer chemotherapy (Immunotherapy (non-antibody-based therapy), retinoid therapy, hormonal therapy within 2 weeks prior to...
- Has received antibody-based anti-cancer therapy within 4 weeks prior to treatment.
- Has received targeted agents and small molecules within 2 weeks or 5 half-lives, whichever is longer.
- Has received prior platinum-based chemotherapy and progressed within 4 weeks of initiating therapy (platinum-refractory disease)
See the full eligibility criteria
- The participant provides written informed consent
- ≥ 18 years of age on day of signing informed consent.
- Participant with histologically or cytologically confirmed diagnosis of advanced unresectable and/or metastatic solid tumors
- A male participant must agree to use contraception and refrain from sperm donation or expecting to father a child
- A female participant is eligible to participate if she is not pregnant, not breastfeeding, not a woman of childbearing potential
- Have measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology
- Able to provide tumor tissue sample.
- Willing to undergo fresh tumor biopsy at Screening and On-treatment if archival tissue not available
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Life expectancy greater than or equal to 12 weeks as judged by the Investigator.
- Have adequate organ function
- A WOCBP who has a positive serum pregnancy test (within 72 hours) prior to treatment.
- Has received prior investigational agents within 4 weeks prior to treatment.
- Has received anti-cancer chemotherapy (Immunotherapy (non-antibody-based therapy), retinoid therapy, hormonal therapy within 2 weeks prior to treatment.
- Has received antibody-based anti-cancer therapy within 4 weeks prior to treatment.
- Has received targeted agents and small molecules within 2 weeks or 5 half-lives, whichever is longer.
- Has received prior platinum-based chemotherapy and progressed within 4 weeks of initiating therapy (platinum-refractory disease)
- Has received an ADC with MMAE payload.
- Has received prior radiotherapy within 2 weeks of start of study treatment for focal radiation or within 4 weeks for wide-field radiotherapy
- Has received G-CSF or GM-CSF within 7 days prior to start of study treatment.
- Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention.
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the...
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has known active CNS metastases and/or carcinomatous meningitis
- Has severe hypersensitivity (≥ Grade 3), known allergy or reaction LNCB74 or any of its excipients.
- Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease.
- Has active ≥Grade 2 sensory or motor neuropathy.
- Has active or chronic corneal disorders, other active ocular conditions requiring ongoing therapy or any clinically significant corneal disease.
- Has an active infection requiring systemic therapy.
- Any major surgery within 4 weeks of study drug administration.
- Toxicity (except for alopecia) related to prior anti-cancer therapy and/or surgery, unless the toxicity is either resolved, returned to baseline or Grade 1, or deemed irreversible.
- Prior organ or tissue allograft.
- Uncontrolled or significant cardiovascular disease
- Participants with serious or uncontrolled medical disorders.
- Participants who are on total parenteral nutrition (TPN)
- Participants with history of bowel obstruction within one month of screening
- Participants with history of significant ascites requiring paracentesis within 2 weeks of screening
- Has a known history of human immunodeficiency virus (HIV) infection with an acquired immune deficiency syndrome (AIDS)-defining opportunistic infection within the last year, or a current CD4 count \<350 cells/µl
- Has known active Hepatitis B (defined as HBsAg reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection
- Has a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full...
- Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
The study team makes the final eligibility decision.
Where it's taking place
- Newport Beach, California, United States
- Edgewood, Kentucky, United States
- Boston, Massachusetts, United States
- St Louis, Missouri, United States
- Hackensack, New Jersey, United States
- Buffalo, New York, United States
- Cleveland, Ohio, United States
- Philadelphia, Pennsylvania, United States
- Pittsburgh, Pennsylvania, United States
- Houston, Texas, United States
- San Antonio, Texas, United States
- Salt Lake City, Utah, United States
- Falls Church, Virginia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Newport Beach, California, United States; Edgewood, Kentucky, United States; Boston, Massachusetts, United States; St Louis, Missouri, United States; Hackensack, New Jersey, United States; Buffalo, New York, United States and 7 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.